The stock has a 36-month beta value of 0.69. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for VTYX is 61.17M, and at present, short sellers hold a 11.30% of that float. On March 28, 2025, the average trading volume of VTYX was 1.28M shares.
VTYX) stock’s latest price update
The stock of Ventyx Biosciences Inc (NASDAQ: VTYX) has decreased by -2.85 when compared to last closing price of 1.23. Despite this, the company has experienced a -9.47% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-02-27 that Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson’s disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications.
VTYX’s Market Performance
VTYX’s stock has fallen by -9.47% in the past week, with a monthly drop of -17.59% and a quarterly drop of -47.36%. The volatility ratio for the week is 5.57% while the volatility levels for the last 30 days are 7.09% for Ventyx Biosciences Inc The simple moving average for the past 20 days is -13.52% for VTYX’s stock, with a -44.21% simple moving average for the past 200 days.
Analysts’ Opinion of VTYX
Many brokerage firms have already submitted their reports for VTYX stocks, with Wells Fargo repeating the rating for VTYX by listing it as a “Overweight.” The predicted price for VTYX in the upcoming period, according to Wells Fargo is $16 based on the research report published on March 12, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see VTYX reach a price target of $12. The rating they have provided for VTYX stocks is “Outperform” according to the report published on March 12th, 2024.
Wells Fargo gave a rating of “Equal Weight” to VTYX, setting the target price at $8 in the report published on November 07th of the previous year.
VTYX Trading at -27.23% from the 50-Day Moving Average
After a stumble in the market that brought VTYX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.95% of loss for the given period.
Volatility was left at 7.09%, however, over the last 30 days, the volatility rate increased by 5.57%, as shares sank -25.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.80% lower at present.
During the last 5 trading sessions, VTYX fell by -10.61%, which changed the moving average for the period of 200-days by -65.70% in comparison to the 20-day moving average, which settled at $1.3810. In addition, Ventyx Biosciences Inc saw -45.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VTYX starting from Nuss John, who sale 21,119 shares at the price of $2.36 back on Dec 27 ’24. After this action, Nuss John now owns 464,582 shares of Ventyx Biosciences Inc, valued at $49,841 using the latest closing price.
Nuss John, the Officer of Ventyx Biosciences Inc, proposed sale 21,119 shares at $2.36 during a trade that took place back on Dec 27 ’24, which means that Nuss John is holding shares at $49,842 based on the most recent closing price.
Stock Fundamentals for VTYX
The total capital return value is set at -0.56. Equity return is now at value -54.27, with -48.36 for asset returns.
Based on Ventyx Biosciences Inc (VTYX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -12.12.
Currently, EBITDA for the company is -148.45 million with net debt to EBITDA at 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.97.
Conclusion
To sum up, Ventyx Biosciences Inc (VTYX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
